Back to Pharma & Biotech Public Relations

 

XIFAXAN

Coyne PR provides public relations strategy to support Salix’s lead brand, XIFAXAN, which is indicated for irritable bowel syndrome with diarrhea (IBS-D) and overt hepatic encephalopathy (OHE).  The agency creates campaigns to engage key audiences in new and creative ways.  Our efforts include editor events with nationally renowned clinical and research experts, media tours and digital/VR content to educate key audiences about the biology of the gut microbiota, a key factor underpinning IBS-D.